EC Microbiology

Review Article Volume 22 Issue 5 - 2028

Non-Alcoholic Steatohepatitis and Intestinal Microbiome

Álvaro Zamudio Tiburcio1*, Héctor Bermúdez Ruiz2, Silverio Alonso López3 and Pedro Antonio Reyes López4

1Department of Gastroenterology, Intestinal Microbiota Transplantation, Medical Specialties, Naples Unit, Mexico
2Endoscopy Service, Oncology Hospital, National Medical Center, XXI Century, Mexican Social Security Institute, Mexico
3Department of Urologist, Chairman Medical Specialties Naples in Mexico City, Mexico
4Immunologist, Rheumatologist, National Institute of Cardiology “I. Chávez”, Mexico City, Mexico

*Corresponding Author: Álvaro Zamudio Tiburcio, Department of Gastroenterology, Intestinal Microbiota Transplantation, Medical Spe- cialties, Naples Unit, Mexico.
Received: March 24, 2026; Published: April 29, 2026



Non-alcoholic steatohepatitis (NASH) is a progressive liver disease characterized by fat accumulation, inflammation, and damage to liver cells, often linked to metabolic dysfunction. It commonly presents with overweight, type 2 diabetes, elevated cholesterol, and high blood pressure, as well as excess fat in the liver. Now, we will examine this frequent and aggressive pathology and its relation- ship with the gut microbiome. Our aim is to identify processes that can minimize the impact of NASH and, consequently, guide new treatments for its management.

Keywords:Non-Alcoholic Steatohepatitis (NASH); Intestinal Microbiome (GM); Non-Alcoholic Fatty Liver Disease (NAFLD)

  1. Sanyal AJ., et al. “Prospective study of outcomes in adults with nonalcoholic fatty liver disease. clinical research network”. New England Journal of Medicine17 (2021): 1559-1569.
  2. Kanwal S., et al. “Frequency of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus and its associated risk factors”. Pakistan Journal of Medical Sciences5 (2021): 1335-1341.
  3. Zhu B., et al. “Non-alcoholic steatohepatitis pathogenesis, diagnosis, and treatment”. Frontiers in Cardiovascular Medicine 8 (2021): 742382.
  4. Tamaki N., et al. “Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD”. Nature Reviews Endocrinology 1 (2022): 55-66.
  5. Alwahaibi N and Alwahaibi M. “Liver biopsy in the modern era: from traditional techniques to artificial intelligence and multi-omics integration”. Frontiers in Medicine 12 (2025): 1678753.
  6. Mpountouridis A., et al. “Gut microbiome in non-alcoholic fatty liver disease”. Frontiers in Gastroenterology 3 (2025): 1534431.
  7. Long C., et al. “Intestinal barrier dysfunction and gut microbiota in non-alcoholic fatty liver disease: assessment, mechanisms, and therapeutic considerations”. Biology4 (2024): 243.
  8. Xiang H., et al. “The role of the intestinal microbiota in nonalcoholic steatohepatitis”. Frontiers in Endocrinology 13 (2022): 812610.
  9. Pezzino S., et al. “Gut-liver axis and non-alcoholic fatty liver disease: a vicious circle of dysfunctions orchestrated by the gut microbiome”. Biology11 (2022): 1622.
  10. Collins SL., et al. “Bile acids and the gut microbiota: metabolic interactions and impacts on disease”. Nature Reviews Microbiology 21 (2023): 236-247.
  11. Tyagi A and Kumar V. “The gut microbiota-bile acid axis: a crucial regulator of immune function and metabolic health”. World Journal of Microbiology and Biotechnology 41 (2025): 215.
  12. Savari F and Mard SA. “Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment”. Heliyon7 (2024): e28468.
  13. Paternostro R and Trauner M. “Current treatment of non-alcoholic fatty liver disease”. Journal of Internal Medicine 2 (2022): 190-204.
  14. Wei W., et al. “Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid”. Nature Microbiology 8 (2023): 1534-1548.
  15. Cao C., et al. “Effects of probiotics on non-alcoholic fatty liver disease: a review of human clinical trials”. Frontiers in Nutrition 10 (2023): 1155306.
  16. Kaufmann B., et al. “Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease”. American Journal of Physiology-Gastrointestinal and Liver Physiology1 (2023): G42-G61.
  17. Fadhilah J., et al. “Effect of synbiotic supplementation on liver function, metabolic profile and gut microbiota in non-alcoholic fatty liver disease (NAFLD): A meta-analysis of randomized controlled trials”. Clinical Nutrition Open Science 56 (2024): 128-151.
  18. Xue LF., et al. “Fecal microbiota transplantation for the treatment of nonalcoholic fatty liver disease”. Exploratory Research and Hypothesis in Medicine 1 (2019): 12-18.
  19. Qiu XX., et al. “Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect”. World Journal of Gastroenterology 8 (2024): 833-842.
  20. Xue L., et al. “Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial”. Frontiers in Cellular and Infection Microbiology 12 (2022): 759306.
  21. Thomas Christos. “Complications of steatohepatitis and nonalcoholic fatty liver disease”. Clinical and Medical Biochemistry 9 (2023): 147.
  22. Francque SM., et al. “Non-alcoholic fatty liver disease: A patient guideline”. JHEP Reports5 (2021): 100322.
  23. Kim Y., et al. “Progression from non-alcoholic steatohepatitis to advanced liver diseases and mortality among medicare patients”. Advances in Therapy 41 (2024): 4335-4355.

Álvaro Zamudio Tiburcio., et al. “Non-Alcoholic Steatohepatitis and Intestinal Microbiome”. EC Microbiology 22.5 (2026): 01-05.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net